Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF 156-B7-100 from R&D Systems, a Bio-Techne Brand

Product Specs
ItemRecombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF
CompanyR&D Systems, a Bio-Techne Brand
Price $425.00Supplier Page View Company Product Page
Catalog Number156-B7-100
Size100 ug (also 1 mg)
FormatLyophilized from a 0.2 µm filtered solution in PBS and NaCl
Purity>90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining
ApplicationsBioactivity
Conjugate/TagUnconjugated
SpeciesHuman
Molecule NamePD-L1/B7-H1
Molecular WeightObserved: 70-75 kDa, reducing conditions
Theoretical: 52 kDa (monomer)
Source/Expression SystemNS0-derived Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF
NCBI Full Gene NameCD274 molecule
NCBI Gene AliaseshPD-L1, B7H1, PDL1, PD-L1, PDCD1L1, B7-H, PDCD1LG1
StorageUse a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution

Add to Compare List

R&D Systems, a Bio-Techne Brand

614 McKinley Place N.E.

Minneapolis, Minnesota 55413

United States

Phone: 1 (800) 343-7475
1 (612) 379-2956

Fax: 1 (612) 656-4400

Company Profile

Website: http://www.rndsystems.com

(1) Simultaneous secretion of a PD-L1 x 4-1BB bispecific antibody improves antileukemic efficacy of STAb-T cells secreting a CD19-specific T-cell engagerOncoimmunologyDecember 31, 2025Marina Gómez-Rosel, Laura Rubio-Pérez, Ivana Zagorac, Carmen Domínguez-Alonso, Laura Díez-Alonso, Oana Hangiu, Rocío Navarro, Raúl Torres-Ruíz, Sandra Rodríguez-Perales, Francisco J. Blanco, et al.(ELISA) Human CD19-Fc (5 μg/mL) (Cat. No. 9269-CD−050, R&D Systems), human PD-L1-Fc (2.5 μg/mL) (Cat. No. 156-B7−100, R&D Systems), or human 4-1BB-Fc (2.5 μg/mL) (Cat. No. 838-4B−100, R&D Systems) chimeras were immobilized

(2) Simultaneous secretion of a PD-L1 x 4-1BB bispecific antibody improves antileukemic efficacy of STAb-T cells secreting a CD19-specific T-cell engagerOncoimmunologyOctober 26, 2025Marina Gómez-Rosel, Laura Rubio-Pérez, Ivana Zagorac, Carmen Domínguez-Alonso, Laura Díez-Alonso, Oana Hangiu, Rocío Navarro, Raúl Torres-Ruíz, Sandra Rodríguez-Perales, Francisco J. Blanco, et al.(ELISA) Human CD19-Fc (5 μg/mL) (Cat. No. 9269-CD−050, R&D Systems), human PD-L1-Fc (2.5 μg/mL) (Cat. No. 156-B7−100, R&D Systems), or human 4-1BB-Fc (2.5 μg/mL) (Cat. No. 838-4B−100, R&D Systems) chimeras were immobilized

(3) Gal-3 blocks the binding between PD-1 and pembrolizumabJournal for immunotherapy of cancerOctober 2, 2024Greisen SR, Bendix M, Nielsen MA, Pedersen K, Jensen NH, Hvid M, Mikkelsen JH, Drace T, Boesen T, Steiniche T, et al.2 mM CaCl2 and 0.05% Tween-20. PD-1 (rhPD-1, R&D systems, 1086-PD) and PD-L1 (rhPD-L1, R&D systems, 156-B7-100) were both recombinant Fc-fused proteins. Gal-3 (kindly provided by Professor Hakon Leffler) was recombinantly

(4) LAMTOR1 decreased exosomal PD-L1 to enhance immunotherapy efficacy in non-small cell lung cancerMolecular cancerSeptember 2, 2024Wu B, Huang X, Shi X, Jiang M, Liu H, Zhao L.

(5) Epithelial-mesenchymal transition induced by tumor cell-intrinsic PD-L1 signaling predicts a poor response to immune checkpoint inhibitors in PD-L1-high lung cancerBritish journal of cancerJuly 1, 2024Jeong H, Koh J, Kim S, Song SG, Lee SH, Jeon Y, Lee CH, Keam B, Lee SH, Chung DH, et al.

(6) Secondary metabolites of mulberry leaves exert anti-lung cancer activity through regulating the PD-L1/PD-1 signaling pathwayJournal of pharmaceutical analysisJune 1, 2024Ye G, Sun X, Li J, Mai Y, Gao R, Zhang J.Dalian, China), interleukin-2 (IL-2) (Cat. No. 589102; BioLegend, San Diego, CA, USA), PD-L1 (Cat. No. 156-B7-100; Novus Biologicals, Littleton, CO, USA), and PD-1 (Cat. No. Z03370; GenScript, Nanjing, China). Reagents

(7) Novel ultrasensitive automated kinetic exclusion assay for measurement of plasma levels of soluble PD-L1, the predictive and prognostic biomarker in cancer patients treated with immune checkpoint inhibitorsHeliyonMay 30, 2024Darwish IA, Alahmad W, Vinoth R.

(8) Characterization of a Trispecific PD-L1 Blocking Antibody That Exhibits EGFR-Conditional 4-1BB Agonist ActivityAntibodies (Basel)April 24, 2024Laura Rubio-Pérez, Susana Frago, Marta Compte, Rocío Navarro, Seandean L. Harwood, Rodrigo Lázaro-Gorines, Marina Gómez-Rosel, Oana Hangiu, Noelia Silva-Pilipich, Lucía Vanrell, et al.(hEGFR-Fc, R&D Systems, Minneapolis, MN, USA; cat# 344-ER), human PD-L1-Fc (hPD-L1-Fc, R&D Systems, cat# 156-B7-100), or human 4-1BB-Fc (h4-1BB-Fc, R&D Systems, cat# 838-4B-100) chimeras were immobilized (2.5 µg/mL in

(9) Identification of the functional PD-L1 interface region responsible for PD-1 binding and initiation of PD-1 signalingThe Journal of biological chemistryDecember 1, 2023Carter R, Alanazi F, Sharp A, Roman J, Luchini A, Liotta L, Paige M, Brown AM, Haymond A.(500 μM, 100 μM, or 10 μM) from Peptide 2.0 or 1 μM recombinant human PD-L1 (R&D systems, Cat. No. 156-B7-100) for 30 min prior to co-culture. After 30 min, media was removed from OVCAR8 wells and replaced with

(10) PD-1 signaling uncovers a pathogenic subset of T cells in inflammatory arthritisbioRxiv : the preprint server for biologyNovember 17, 2023Straube J, Bukhari S, Lerrer S, Winchester R, Henick B, Dragovich M, Mor A.

(11) A Comparison of the Antitumor Efficacy of Novel Multi-Specific Tribodies with Combinations of Approved Immunomodulatory AntibodiesCancersNovember 9, 2023Manna L, Rapuano Lembo R, Yoshioka A, Nakamura K, Passariello M, De Lorenzo C.

(12) Rational design of PD-1-CD28 immunostimulatory fusion proteins for CAR T cell therapyBritish journal of cancerSeptember 1, 2023Lorenzini T, Cadilha BL, Obeck H, Benmebarek MR, Märkl F, Michaelides S, Strzalkowski T, Briukhovetska D, Müller PJ, Nandi S, et al.

(13) In vitro and in vivo studies of plant-produced Atezolizumab as a potential immunotherapeutic antibodyScientific reportsAugust 29, 2023Rattanapisit K, Bulaon CJI, Strasser R, Sun H, Phoolcharoen W.

(14) Identification of Small Molecules Affecting the Secretion of Therapeutic Antibodies with the Retention Using Selective Hook (RUSH) SystemCellsJune 16, 2023Coulet M, Lachkar S, Leduc M, Trombe M, Gouveia Z, Perez F, Kepp O, Kroemer G, Basmaciogullari S.

(15) Hyperprogression of cutaneous T cell lymphoma after anti-PD-1 treatmentJCI insightFebruary 22, 2023Gao Y, Hu S, Li R, Jin S, Liu F, Liu X, Li Y, Yan Y, Liu W, Gong J, et al.μg/mL, R&D Systems, 110-HG-100) as the control or human PD-L1 Fc Chimera Protein (10 μg/mL, R&D Systems, 156-B7-100) overnight at 4°C. The cells were seeded in duplicate plates at a density of 1 × 105 cells/100 μL medium.

(16) Galectin-3 interacts with PD-1 and counteracts the PD-1 pathway-driven regulation of T cell and osteoclast activity in Rheumatoid ArthritisScandinavian journal of immunologyFebruary 1, 2023Pedersen K, Nielsen MA, Juul-Madsen K, Hvid M, Deleuran B, Greisen SR.35 kindly provided by Prof. Hakon Leffler), rhPD‐1 (R&D systems, 1086‐PD) and rhPD‐L1 (R&D systems, 156‐B7‐100). PD‐1 or PD‐L1 was immobilized on the surface by protein G coupling. Increasing concentrations of rhGal‐3

(17) Fluid nanoporous microinterface enables multiscale-enhanced affinity interaction for tumor-derived extracellular vesicle detectionProceedings of the National Academy of Sciences of the United States of AmericaNovember 1, 2022Niu Q, Gao J, Zhao K, Chen X, Lin X, Huang C, An Y, Xiao X, Wu Q, Cui L, et al.antibody (anti-PD-L1, cat. no. MAB1561), and Recombinant Human PD-L1/B7-H1 Protein (PD-L1, cat. no. 156-B7-100) were bought from R&D systems. Rabbit monoclonal anti-EpCAM antibody (cat. no. ab223582) was purchased

(18) Active PD-L1 incorporation within HIV virions functionally impairs T follicular helper cellsPLoS pathogensJuly 1, 2022Munoz O, Banga R, Schelling R, Procopio FA, Mastrangelo A, Nortier P, Ohmiti K, Daraspe J, Cavassini M, Fenwick C, et al.

(19) High Mobility Group Protein B1 Decreases Surface Localization of PD-1 to Augment T-cell ActivationCancer immunology researchJuly 1, 2022Gao Q, Wang S, Li F, Lian J, Cheng S, Yue D, Zhang Z, Liu S, Ren F, Zhang D, et al.

(20) Cell-targeted PD-1 agonists that mimic PD-L1 are potent T cell inhibitorsJCI insightOctober 22, 2021Curnock AP, Bossi G, Kumaran J, Bawden LJ, Figueiredo R, Tawar R, Wiseman K, Henderson E, Hoong SJ, Gonzalez V, et al.

Be the First to Write a Review!

Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF

PD-L1/B7-H1 Fc Chimera Protein

PD-L1/B7-H1 Fc Chimera Protein

Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF from R&D Systems, a Bio-Techne Brand

Description

R&D Systems, a Bio-Techne Brand

Citations (48)

Reviews

Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF from R&D Systems, a Bio-Techne Brand

About Biocompare

Advertise with Us

Specialized Search Tools

Site Map